Elvina Almuradova· @Dr_ElvinaA · X·· 23 hours agoScore70
Body · original
HEALER: anbenitamab + HB1801 vs THP in HER2+ BC.
Median PFS: not reached vs 14.3 months
▪️HR 0.46 (95% CI 0.37–0.56)
24-month PFS: 58.5% vs 34.4%
An encouraging signal—longer follow-up and OS data will be key. #BCSM @myESMO @Larvol @KolPulseAI @OncoAlert #ESMO26
1 view · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA15matched by Proffered paper 2: Breast cancer, early and advanced stage
Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.orgLBA80matched by Rapid oral 1: Gastrointestinal tumour, upper digestive
Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
https://esmocongress.esmo.orgSource: Elvina Almuradova · x.com